Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Patent metadata

Field	Value
Publication number	US-12129255-B2
Application number	US-202017268107-A
Country	US
Kind code	B2
Filing date	Jun 17, 2020
Priority date	Jun 19, 2019
Publication date	Oct 29, 2024
Grant date	Oct 29, 2024

Abstract

The compoundand pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

First claim

What is claimed is:

1. A compound of

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition according to claim 2 , wherein the composition is suitable for oral administration, for intramuscular injection, or for subcutaneous injection.

4. A method of treating HIV infection in a human comprising administration of an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1 to the human.

5. The method of claim 4 wherein said administration is oral.

6. The method of claim 4 wherein said administration is intramuscular injection or subcutaneous injection.

7. The method of claim 4 wherein said method further comprises administration of at least one other agent used for treatment of HIV infection in a human.

8. The method of claim 7 wherein the at least one other agent is selected from the group consisting of abacavir, atazanavir, bictegravir, cabotegravir, dolutegravir, darunavir, doravirine, fostemsavir, lamivudine, maraviroc, rilpivirine, tenofovir disoproxil, tenofovir, and tenofovir alafenamide.

9. The method of claim 8 wherein the at least one other agent is selected from the group consisting of dolutegravir, lamivudine, fostemsavir, and cabotegravir.

10. A compound which is:

11. A pharmaceutical composition comprising the compound according to claim 10 , and a pharmaceutically acceptable excipient.

12. The pharmaceutical composition according to claim 11 , wherein the composition is suitable for oral administration, for intramuscular injection, or for subcutaneous injection.

13. A method of treating HIV infection in a human comprising administration of a therapeutically effective amount of the compound according to claim 10 to the human.

14. The method of claim 13 wherein said administration is oral.

15. The method of claim 13 wherein said administration is via intramuscular injection.

16. The method of claim 13 wherein said administration is via subcutaneous injection.

17. The method of claim 13 wherein said method further comprises administration of at least one other agent used for treatment of HIV infection in a human.

18. The method of claim 17 wherein the at least one other agent is selected from the group consisting of abacavir, atazanavir, bictegravir, cabotegravir, dolutegravir, darunavir, doravirine, fostemsavir, lamivudine, maraviroc, rilpiverine, tenofovir disoproxil, tenofovir, and tenofovir afenamide.

19. The method of claim 17 wherein the at least one other agent is selected from the group consisting of dolutegravir, lamivudine, fostemsavir, and cabotegravir.

20. The method of claim 17 wherein the at least one other agent is cabotegravir.

21. The method of claim 17 wherein the at least one other agent is dolutegravir.

Assignees

• Viiv Healthcare Uk No 5 Ltd

Inventors

• Gillis Eric P
• Iwuagwu Christiana

Classifications

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07B2200/07

  Optical isomers · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title